Editor’s pick
Health Canada has approved Aspen's copy of Ozempic, but the supplier of its key ingredient has halted production until at least late October, leaving the company with a licence and no launch date.
Editor’s pick
Saul Saltzman has resigned from the Dis-Chem board after a 25-year career at the company, leaving his father Ivan as the only member of the founding family still holding a seat.
The oil major is offloading most of its venture portfolio to Nordic investor Verdane, a quiet unwinding of its energy-transition experiment.
The lender wants to cut up to 1,200 jobs and close 90 branches after acquisitions left its costs running ahead of its income.
The R773 billion manager has cut its bet on AI chipmakers and moved the money to India, warning the price of hope has climbed too high.
FNB's latest survey finds a jump in retirement planning — and a warning from those already retired that it costs far more than they budgeted.
Big story
A record 142,472 new subscribers in three months pushed owner Karooooo to record profit — even as a stronger rand worked against it.
Recruiters say most IT applicants don't meet the bar for the roles on offer, but others argue the real gap is experience, not qualifications.
Editor’s pick
A BYD finance deal and a set of much-improved results are two halves of the same turnaround story.
Big story
Alan Knott-Craig wants companies to pay 3% of revenue for automatic empowerment credentials. Not everyone calls it a levy.
A regulatory filing reveals what Netflix paid for Ben Affleck's AI startup, and what the tools actually do.
A collapsed Middle East ceasefire has lit a fire under oil, Sasol shares and the odds of another rate hike.